Exciting Progress in Targeted Therapy Innovation for Unresectable Stage III EGFR-mutated NSCLC: the Phase III LAURA Study

Overview

Journal Cancer Commun (Lond)

Publisher Wiley

Specialty Oncology

Date 2024 Oct 10

PMID 39387214

Authors

Ziyan Tong

Ning Zhu

Hong Shen

Ying Yuan

Affiliations

Soon will be listed here.

Citing Articles

Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study.

Tong Z, Zhu N, Shen H, Yuan Y Cancer Commun (Lond). 2024; 44(12):1381-1384.

PMID: 39387214 PMC: 11666994. DOI: 10.1002/cac2.12611.

References

Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J . Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10):1830-1840. PMC: 10082285. DOI: 10.1200/JCO.22.02186. View

Akamatsu H, Murakami H, Harada H, Shimizu J, Hayashi H, Daga H . Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. J Thorac Oncol. 2021; 16(10):1745-1752. DOI: 10.1016/j.jtho.2021.05.019. View

Spigel D, Faivre-Finn C, Gray J, Vicente D, Planchard D, Paz-Ares L . Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12):1301-1311. PMC: 9015199. DOI: 10.1200/JCO.21.01308. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Xing L, Wu G, Wang L, Li J, Wang J, Yuan Z . Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2020; 109(5):1349-1358. DOI: 10.1016/j.ijrobp.2020.11.026. View

Naidoo J, Antonia S, Wu Y, Cho B, Thiyagarajah P, Mann H . Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. J Thorac Oncol. 2023; 18(5):657-663. DOI: 10.1016/j.jtho.2023.02.009. View

Bi N, Xu K, Ge H, Chen M, E M, Zhang L . Real-world treatment patterns and clinical outcomes in -mutant locally advanced lung adenocarcinoma: A multi-center cohort study. J Natl Cancer Cent. 2024; 3(1):65-71. PMC: 11256516. DOI: 10.1016/j.jncc.2022.11.003. View

Lu S, Kato T, Dong X, Ahn M, Quang L, Soparattanapaisarn N . Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC. N Engl J Med. 2024; 391(7):585-597. DOI: 10.1056/NEJMoa2402614. View

Tong Z, Zhu N, Shen H, Yuan Y . Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study. Cancer Commun (Lond). 2024; 44(12):1381-1384. PMC: 11666994. DOI: 10.1002/cac2.12611. View

10.

Nassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C . Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024; 19(6):928-940. DOI: 10.1016/j.jtho.2024.01.012. View